News Home

Amgen, Inc. (AMGN) Stock: What Does the Chart Say Tuesday?

Tuesday, January 25, 2022 01:59 PM | InvestorsObserver Analysts
Amgen, Inc. (AMGN) Stock: What Does the Chart Say Tuesday?

The market has been down on Amgen, Inc. (AMGN) stock recently. AMGN gets a Bearish score from InvestorsObserver Stock Sentiment Indicator.

Sentiment Score - ,bearish
Amgen, Inc. has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on AMGN!

What is Stock Sentiment?

In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company. Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish. InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion. For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What's Happening With AMGN Stock Today?

Amgen, Inc. (AMGN) stock has gained 0.46% while the S&P 500 has fallen -1% as of 1:57 PM on Tuesday, Jan 25. AMGN has risen $1.05 from the previous closing price of $226.08 on volume of 1,157,572 shares. Over the past year the S&P 500 is up 13.25% while AMGN has fallen -11.66%. AMGN earned $9.71 a per share in the over the last 12 months, giving it a price-to-earnings ratio of 23.39. To screen for more stocks like Amgen, Inc. click here.

More About Amgen, Inc.

Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Nexavar and Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), and Lumakras (lung cancer). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira). Click Here to get the full Stock Report for Amgen, Inc. stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App